IP Library Patent Application 18043804
Patent Application
App. No. 18/043,804

METHOD FOR DETERMINING TITER OF RNA VIRAL VECTORS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/043,804
Abstract

The present disclosure provides methods for rapidly assaying the titer of an RNA viral vector such as a lentiviral vector. The method can be used to quickly evaluate the titer of intermediate products in various steps of a lentiviral vector production process.

Claims (22)

1 . A method for determining a titer of an RNA viral vector in a sample, the method comprising:

(a) providing a sample comprising an RNA viral vector and DNA molecules, or adding DNA molecules to a sample comprising an RNA viral vector, wherein both the RNA viral vector and the DNA molecules comprise a sequence element;

(b) obtaining a first portion and a second portion from the sample; and

(c) performing polymerase chain reaction (PCR) on the first portion to determine a copy number of the sequence element in the first portion (n1), and performing reverse transcription PCR (RT-PCR) on the second portion to determine a copy number of the sequence element in the second portion (n2), wherein an RNA copy number of the RNA viral vector in the sample is determined by a difference between n1 and n2 which is n2−n1.

2 . The method of claim 1 , further comprising (d) determining an infectious titer of the RNA viral vector based on the RNA copy number of the RNA viral vector in the sample.

3 . The method of claim 1 , wherein the RNA viral vector is a retroviral vector.

4 . The method of claim 3 , wherein the retroviral vector is a lentiviral vector.

5 . The method of claim 1 , wherein the sequence element is a regulatory element.

6 . The method of claim 5 , wherein the regulatory element is a woodchuck hepatitis virus posttranscriptional regulatory element (WPRE).

7 . The method of claim 1 , wherein the sequence element is a long terminal repeat (LTR) or a promoter.

8 . The method of claim 1 , wherein the PCR uses a primer pair to amplify a region of the sequence element.

9 . The method of claim 1 , wherein the RT-PCR uses a primer pair to amplify a region of the sequence element.

10 . The method of claim 1 , wherein the PCR and the RT-PCR use a primer pair to amplify a region of the sequence element, respectively.

11 . The method of claim 8 , wherein the primer pair comprises two primers comprising nucleotide sequences set forth in: (i) SEQ ID NO: 1 and SEQ ID NO: 2, respectively; (ii) SEQ ID NO: 3 and SEQ ID NO: 4, respectively; or (iii) SEQ ID NO: 5 and SEQ ID NO: 6, respectively.

12 . The method of claim 1 , wherein the PCR is quantitative PCR (qPCR), and the RT-PCR is RT-qPCR.

13 . The method of claim 1 , wherein the titer is a physical titer or an infectious titer.

14 . The method of claim 1 , wherein the DNA molecules are DNA plasmids.

15 . The method of claim 14 , wherein the DNA plasmids are packaging plasmids.

16 . The method of claim 2 , wherein the infectious titer of the RNA viral vector is determined by: (the RNA copy number of the RNA viral vector×an infectious titer of a positive control)/a RNA copy number of the positive control, wherein the positive control is an RNA viral vector with a known infectious titer.

17 . The method of claim 2 , wherein the titer of the RNA viral vector is determined within 2 hours.

18 . The method of claim 9 , wherein the primer pair comprises two primers comprising nucleotide sequences set forth in: (i) SEQ ID NO: 1 and SEQ ID NO: 2, respectively; (ii) SEQ ID NO: 3 and SEQ ID NO: 4, respectively; or (iii) SEQ ID NO: 5 and SEQ ID NO: 6, respectively.

19 . The method of claim 10 , wherein the primer pair comprises two primers comprising nucleotide sequences set forth in: (i) SEQ ID NO: 1 and SEQ ID NO: 2, respectively; (ii) SEQ ID NO: 3 and SEQ ID NO: 4, respectively; or (iii) SEQ ID NO: 5 and SEQ ID NO: 6, respectively.

Assignments (2)
CHANGE OF NAME Recorded Jan 17, 2024
From: CELLULAR BIOMEDICINE GROUP, INC.
To: ABELZETA INC.
Reel/Frame 066340/0795 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 15, 2023
From: WANG, ZEFA; LI, LI; ZHANG, HANNING; CAO, YILANG; HAN, TING; LU, JISHUN; HONG, YI; ZHANG, LI
To: CELLULAR BIOMEDICINE GROUP, INC.
Reel/Frame 063642/0283 →